NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies, Inc. (Nasdaq: NEOC) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics and drug delivery methods for intracranial malignancies, including primary brain cancers such as glioblastoma and meningioma, as well as secondary brain cancers from metastatic spread. The… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What NEONC TECHNOLOGIES HOLDINGS, INC. does
In the company’s own words
NeOnc Technologies, Inc. (Nasdaq: NEOC) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics and drug delivery methods for intracranial malignancies, including primary brain cancers such as glioblastoma and meningioma, as well as secondary brain cancers from metastatic spread. The company was founded in 2008 and operates through its website at www.neonc.com.
The company's lead product candidate, NEO100, is a purified form of perillyl alcohol administered via intranasal delivery to bypass the blood-brain barrier. NEO100 has received orphan drug designation from the FDA for treating malignant glioma and is currently in Phase IIa clinical trials for patients with recurrent high-grade gliomas harboring IDH1 mutations and for patients with malignant skull-based meningioma. Phase I results demonstrated that intranasal NEO100 was well tolerated with minimal side effects, and certain patient subsets showed extended survival compared to historical benchmarks.
NeOnc's second lead product, NEO212, is a covalently conjugated hybrid molecule combining temozolomide with perillyl alcohol, designed to enhance blood-brain barrier penetration. NEO212 has received orphan drug designation for three indications: glioma, brain metastases from breast cancer, and nasopharyngeal carcinoma. The compound completed preclinical testing and received FDA investigational new drug approval, with Phase I/II clinical trials initiated in the fourth quarter of 2023 for oral administration in patients with primary and secondary brain tumors.
The company is exploring three distinct drug delivery pathways enabled by NEO100: intranasal delivery for direct nose-to-brain transport, stable conjugation to other therapeutic agents, and intra-arterial injection to temporarily open the blood-brain barrier. In 2025, NeOnc acquired an intellectual property portfolio comprising artificial intelligence-driven drug discovery tools, rapid magnetic 3D bioprinting technology, and quantum molecular modeling capabilities to enhance preclinical and clinical research activities.
As a clinical-stage company, NeOnc has no approved commercial products, no sales infrastructure, and no reportable revenue segments. The company focuses entirely on research and development activities to advance its product candidates through regulatory approval pathways.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CALABASAS, CA
- Fiscal year end
- December
- CIK
- 1979414
- SIC
- 2834
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns NEONC TECHNOLOGIES HOLDINGS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · NEONC TECHNOLOGIES HOLDINGS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do NEONC TECHNOLOGIES HOLDINGS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of NEONC TECHNOLOGIES HOLDINGS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in NEONC TECHNOLOGIES HOLDINGS, INC.'s last four quarterly filings that the numbers alone won't show?”